Search Results
108 items found for "pancreatic cancer"
- 📰 GPCR Weekly News, October 16 to 22, 2023
reinforces consistent reduction in risk of recurrence across key subgroups of patients with early breast cancer
- 📰 GPCR Weekly News, April 3 to 9, 2023
GPCR Events, Meetings, and Webinars NEW AACR 2023 - American Association for Cancer Research (April 14
- 📰 GPCR Weekly News, September 18 to 24, 2023
protein-coupled receptor 37 promotes resistance to cisplatin-induced apoptosis in non-small cell lung cancer
- 📰 GPCR Weekly News, March 11 to 17, 2024
Therapeutics and Chime Biologics announce manufacturing agreement to advance novel anti-CCR8 antibody for cancer
- 📰 GPCR Weekly News, February 26 to March 3, 2024
endocrinology and metabolism Reviews, GPCRs, and more Butyrate as a promising therapeutic target in cancer
- 📰 GPCR Weekly News, September 4 to 10, 2023
and Immunology [1,2,4]Triazolo[1,5-c]pyrimidines as Tools to Investigate A3 Adenosine Receptors in Cancer
- 📰 GPCR Weekly News, August 28 to September 3, 2023
back again: the lysophosphatidic acid-CCN axis in signal transduction NPFF stimulates human ovarian cancer
- 📰 GPCR Weekly News, February 5 to 11, 2024
News Exscientia Initiates Clinical Study to Further Evaluate Functional Precision Medicine Platform in Cancer
- Unlocking the Future of Medicine: Advancements in GPCR Research
Reviews, GPCRs, and more Lessons from the physiological role of guanosine in neurodegeneration and cancer
- 📰 GPCR Weekly News, July 31 to August 6, 2023
fibroblast heterogeneity in fibroblast-associated diseases Ultrasensitive dose-response for asbestos cancer
- 📰 GPCR Weekly News, April 10 to 16, 2023
4256, a Highly Potent and Selective Inhibitor of GPR65, in Presentation at American Association for Cancer
- 📰 Breaking Down the Latest GPCR Discoveries: a Weekly Update (Nov 27-Dec 3, 2023)
Oncology and Immunology Expression prevalence and dynamics of GPCR somatostatin receptors 2 and 3 as cancer
- 📰 GPCR Weekly News, November 20 to 26, 2023
Microbiota Effects on the Immune System, and Western Diseases Lactate receptor GPR81 drives breast cancer
- 📰 GPCR Weekly News, November 13 to 19, 2023
TRUQAP™ (capivasertib) plus fulvestrant approved in the US for patients with advanced HR-positive breast cancer
- 📰 GPCR Weekly News, February 27 to March 5, 2023
GPCRs in Oncology and Immunology GPR143 controls ESCRT-dependent exosome biogenesis and promotes cancer
- 📰 GPCR Weekly News, April 15 to 21, 2024
Deciphering a GPCR-lncRNA-miRNA Nexus: Identification of an Aberrant Therapeutic Target in Ovarian Cancer
- 📰 GPCR Weekly News, March 13 to 19, 2023
Expanding role of CXCR2 and therapeutic potential of CXCR2 antagonists in inflammatory diseases and cancers
- 📰 GPCR Weekly News, January 22 to 28, 2024
parahaemolyticus Involvement of Protease-Activated Receptor2 Pleckstrin Homology Binding Domain in Ovarian Cancer
- 📰 GPCR Weekly News, February 20 to 26, 2023
Small-molecule targeting of GPCR-independent non-canonical G protein signaling inhibits cancer progression
- 📰 GPCR Weekly News, December 11 to 17, 2023
macrophage migration during tissue inflammation From odor to oncology: non-canonical odorant receptors in cancer
- 📰 GPCR Weekly News, January 29 to February 4, 2024
founded by Cumulus Oncology, to develop therapeutics targeting G protein-coupled receptors to treat cancer
- 📰 GPCR Weekly News
Functional Assessment of Cancer-Linked Mutations in Sensitive Regions of Regulators of G Protein Signaling
- 📰 GPCR Weekly News, January 30 to February 5, 2023
Simultaneous activation of CXC chemokine receptor 4 and histamine receptor H1 enhances calcium signaling and cancer
- Unlocking the Therapeutic Potential of Previously Undruggable GPCRs
for a number of inflammatory diseases including atherosclerosis, scleroderma, multiple sclerosis and cancer and efficiently advance a diversified portfolio of GPCR-targeted drug candidates for the treatment of cancer